Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Endocrine 1

Conditions

Sarcoma 4Osteosarcoma 3Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 4Radiotherapy 3Cyclophosphamide 3Carmustine 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3sargramostim 2aldesleukin 2Thalidomide 2Paclitaxel 2Gadolinium DTPA 2Filgrastim 2Donepezil 2Biopsy 2temsirolimus 1surufatinib 1plerixafor 1omburtamab I-131 1ganitumab 1gallium Ga 68 dotatate 1gadobutrol 1gadobenic acid 1entinostat 1cixutumumab 1carboxyamido-triazole 1azurin (50-77) 1antineoplaston AS 2-1 1antineoplaston A10 1adavosertib 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × surufatinib × Sarcoma × Clear all
NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡